Corcept Therapeutics Incorporated CORT
116.10
(2.41)
(2.03%)
as of 25 Sep
- Market cap
- $12.9B
- P/E
- 223×
Follow CORT
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
167.21 | 89.58 | 37.02 | 83.11 |
+8 more quarters Free account |
P/S ratio |
11.03 | 5.47 | 4.75 | 11.61 | |
P/FCF ratio |
85.69 | 35.04 | 25.49 | 52.69 | |
P/Operating CF |
273.16 | (251.00) | 94.01 | 157.96 | |
P/B ratio |
12.98 | 6.60 | 5.58 | 13.62 | |
Price to Tangible BV |
12.98 | 6.60 | 5.58 | 13.62 | |
EV/Sales |
10.66 | 5.04 | 4.27 | 11.05 | |
EV/EBITDA |
2,380.33 | 0.00 | 78.09 | 144.94 | |
EV/Operating CF |
80.76 | 32.19 | 22.87 | 50.06 | |
EV/FCF |
82.86 | 32.27 | 22.90 | 50.14 | |
Quick Ratio |
2.50 | 2.53 | 2.60 | 2.85 | |
Current Ratio |
2.86 | 2.86 | 2.92 | 3.14 | |
Net Debt/EBITDA |
(7.31) | 6.90 | 2,739.77 | (38.93) | |
Debt/Assets |
0.00% | 0.00% | 0.60% | 0.64% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.01 | |
Asset Turnover |
0.98 | 0.93 | 0.91 | 0.92 | |
Operating CF/Net income |
0.80 | 0.54 | 1.61 | 2.81 | |
Capex/Depreciation |
(2.93) | (0.34) | 0.01 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
21.04% | 40.18% | 32.09% | 33.16% | |
Selling, General and Administrative Expense of Revenue |
61.25% | 88.15% | 64.43% | 59.71% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.48% | 13.97% | 10.27% | 11.02% | |
Graham Net Nets |
0.03 | 0.06 | 0.08 | 0.04 | |
Graham Number |
8.85 | 7.86 | 11.49 | 11.72 | |
Earnings Yield |
0.60% | 1.12% | 2.70% | 1.20% | |
Free Cash Flow Yield |
1.17% | 2.85% | 3.92% | 1.90% | |
Revenue per Share |
2.43 | 1.58 | 1.95 | 2.01 | |
Operating CF per Share |
0.32 | (0.16) | 0.37 | 0.53 | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.29 | (0.16) | 0.37 | 0.53 | |
Cash per Share |
2.92 | 3.24 | 3.58 | 4.07 | |
Shareholders Equity per Share |
6.70 | 6.11 | 6.24 | 6.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.70 | 6.11 | 6.24 | 6.10 | |
Free Cash Flow |
31.02 | (16.97) | 38.40 | 54.48 | |
Working Capital |
285.87 | 276.85 | 319.38 | 368.87 | |
Capital Expenditures |
(2.53) | (0.20) | (0.05) | 0.00 | |
Net Current Asset Value |
256.75 | 249.14 | 296.62 | 349.43 | |
EV/EBIT |
1,383.23 | 0.00 | 72.49 | 124.89 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
16.45% | (18.92%) | 11.83% | 9.32% | |
Price to Operating Income |
1,430.53 | 0.00 | 80.68 | 131.24 | |
| Other line items | |||||
Average Receivables |
70.74 | 50.45 | 56.88 | 64.67 | |
Average Payables |
19.22 | 30.63 | 27.91 | 26.52 | |
Average Inventory |
12.73 | 13.63 | 12.64 | 10.20 | |
Average Assets |
845.21 | 830.67 | 838.60 | 803.93 | |
Average Common Equity |
670.78 | 660.64 | 663.70 | 635.37 |
Columns are period end dates